BRIEF-Prometic's drug efficacy further evidenced in Type 2 diabetic and metabolic syndrome clinical trial
April 26 (Reuters) - Prometic Life Sciences Inc
* Prometic's PBI-4050: efficacy further evidenced in type 2 diabetic and metabolic syndrome clinical trial
* New results from additional patients increase statistical and clinical evidence of efficacy
* Reduction of glycated hemoglobin (hba1c) reaches -0.9% (p=0.0004) in patients with hba1c 8% at baseline Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
© Thomson Reuters 2017 All rights reserved.